CLINICAL_TRIALS
trial_result
· 2016-05-13
Clinical Trial Update: Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL [Phase 1]
Summary
Phase 1 trial evaluating weekly subcutaneous alemtuzumab and rituximab for relapsed chronic lymphocytic leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED